Envestnet Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Envestnet Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$363K	Buy	+5,680	New	+$295K	﹤0.01%	4311
2024 Q1	–	Sell	-14,509	Closed	-$254K	–	4236
2023 Q4	$254K	Sell	14,509 -17,677	-55%	-$291K	﹤0.01%	3705
2023 Q3	$559K	Sell	32,186 -19,646	-38%	-$331K	﹤0.01%	3194
2023 Q2	$730K	Sell	51,832 -220,494	-81%	-$2.95M	﹤0.01%	2984
2023 Q1	$219K	Buy	+272,326	New	+$3.59M	﹤0.01%	3613

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Envestnet Asset Management's KNSA Position: Q2 2026 in Review

Envestnet Asset Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 5,680 shares worth $363K. The stake represents ﹤0.01% of the portfolio and ranks #4311 among its holdings. This is a return to the name: Envestnet Asset Management previously reported a position in KNSA as recently as Q4 2023.

Envestnet Asset Management first reported a position in KNSA in Q1 2023 and has held it in 5 quarters since. The position peaked at $730K in Q2 2023. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Envestnet Asset Management held 5,680 shares of Kiniksa Pharmaceuticals worth $363K as of Q2 2026.
Kiniksa Pharmaceuticals was a new Envestnet Asset Management position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4311 holding.
Envestnet Asset Management first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
Envestnet Asset Management's Kiniksa Pharmaceuticals position peaked at $730K in Q2 2023.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.